No 01 2019

SynAct Pharma has reported that resomelagon in combination with methotrexate showed promising clinical effects on par with previous findings with ACR20 reaching 76,4% in the most effective dose compared to 60,8% in the placebo treated control group reaching statistical significance in the subset of patients entering the study with ACR/EULAR class II-III disease.

Johnny Mogensen most recently comes from a position as Denmark’s research and innovation attaché in Boston, USA. He has held several positions in the Danish Agency for Higher Education and Science and has also previously been posted to Brussels as an adviser to Denmark’s EU delegation and as a national expert to the European Commission.

Lionel Leck's research focuses on pediatric cancer, particularly neuroblastoma – one of the most commonly diagnosed childhood cancers with a poor prognosis.

Hansa Biopharma has announced that Fredrik Röök has been appointed as VP Business Development effective August 17.

The two companies have entered into a strategic partnership featuring customized development services for Xdarzane, Xbrane's biosimilar candidate referencing Darzalex (daratumumab).

Camurus has received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for CAM2029 (Oclaiz), a once-monthly octreotide treatment for patients with acromegaly.

Evaxion announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.